Eli Lilly (LLY) Stock Climbs on Foundayo Trial Results Showing 57% Reduction in Death Risk

Eli Lilly (LLY) stock rises as Foundayo obesity pill shows 57% lower death risk and 16% reduction in heart attacks. FDA approval expected Q2 2026.

The post Eli Lilly (LLY) Stock Climbs on Foundayo Trial Results Showing 57% Reduction in Death Risk appeared first on Blockonomi.